Literature DB >> 35979113

Neuroendocrine tumour of the descending part of the duodenum complicated with schwannoma: A case report.

Lu Zhang1, Chi Zhang1, Shu-Yan Feng1, Pan-Pan Ma1, Shuo Zhang1, Qian-Qian Wang2.   

Abstract

BACKGROUND: No known case of neuroendocrine tumour (NET) with schwannoma has been reported. CASE
SUMMARY: A 63-year-old female presented to our hospital with nausea and vomiting. Upper gastrointestinal endoscopy revealed a mass in the descending part of the duodenum. Using ultrasound gastroscopy, we found that the tumour originated from the submucosa and showed low echo. We removed the tumour by electrocoagulation and sent it for pathological biopsy.
CONCLUSION: Immunohistochemical results showed that the mass was a rare NET with neurilemmoma. ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Case report; Duodenum; Endoscopy; Immunohistochemistry; Neuroendocrine tumour; Schwannoma; Trap with current

Year:  2022        PMID: 35979113      PMCID: PMC9258379          DOI: 10.12998/wjcc.v10.i17.5770

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.534


Core Tip: Neuroendocrine tumours (NETs) and schwannomas of the duodenum are quite rare and few clinical cases have been reported. To the best of our knowledge, this is the first publication of a NET of descending duodenum complicated with schwannoma. Through a review of relevant literature, we can deepen the understanding of this type of tumour.

INTRODUCTION

Neuroendocrine tumours (NETs) are rare tumours originating from neuroendocrine cells that account for approximately 2% of all malignant tumours, and approximately 50.6% of NETs are found in the digestive system; duodenal NETs are extremely rare, accounting for only 2%-3% of gastrointestinal NETs[1]. Schwannoma is a benign tumour originating from the nerve fibre sheath, accounting for approximately 5% of all soft tissue tumours; it is mostly located in the body surface and auditory nerve, less often in the digestive tract, and even more rarely in the duodenum[2].

CASE PRESENTATION

Chief complaints

One month of nausea and vomiting.

History of present illness

A 63-year-old female underwent upper gastrointestinal endoscopy at a local, grassroots hospital due to 1 mo of nausea and vomiting, and a large nipple was found in the descending part of the duodenum. The patient’s faecal occult blood test was positive. The patient had obvious symptoms of nausea and vomiting, often vomiting with no stomach contents and had lost 2 kg of weight within a month. Before the operation, we administered symptomatic treatment, such as replenishing gastric protective fluid. After excluding relevant surgical contraindications, endoscopic examination was performed on the patient in our hospital, and we found a protuberant mass above the nipple of the descending duodenum, with a smooth surface and a diameter of approximately 0.5 cm. A 12 MHz ultrasound probe showed that the tumour originated from the submucosa and showed low echo. We used a nylon noose to trap the tumour, cut the bottom of the base by snaring with an electrocurrent, and clamped the wound with a titanium clip to stop the bleeding (Figure 1). To confirm the diagnosis, the excised specimens were sent for pathological examination and immunohistochemistry. One week after the operation, the patient recovered smoothly and was discharged from the hospital. The pathological results showed that the tumour in the descending part of the duodenum was a NET (grade 1) with schwannoma, and the cutting edge was negative (Figure 2). The results of immunohistochemical staining indicated that the tumour cells were positive for antigen KI-67, broad-spectrum cytokeratin, CD56, synaptophysin (Syn), chromogranin A (CgA), S-100, nerve specific enolase, CD68, CD163, and myoglobin and were negative for CD34, succinate dehydrogenase B, CD117, DOG-1, smooth muscle actin, desmin, cytokeratin (CK) 7, CK20, and myogenic differentiation 1 (Figures 3 and 4).
Figure 1

Endoscopic resection of the tumour. A: Tumour in the descending part of the duodenum in the natural state; B: Using endoscopic ultrasonography to explore the tumour; C: Endoscopic electrocoagulation for resection of the tumour; D: A titanium clip was used to clamp the wound to stop the bleeding.

Figure 2

Pathological manifestation of the tumour under a light microscope. A: Pathological tissue (Magnification: 100 ×). The lower right corner is the nesting tissue of the schwannoma, and the rest is the vesicle-like tissue of the neuroendocrine tumour; B: Neuroendocrine tumour tissue (Magnification: 200 ×); C: Schwannoma tissue (Magnification: 200 ×); D: The vertical incisal margin was negative, and there was no lymphatic vascular invasion (Magnification: 400 ×).

Figure 3

Immunohistochemical neuroendocrine tumour results. A: CD56+ (Magnification: 200 ×); B: Chromogranin A+ (Magnification: 200 ×); C: Desmin+ (Magnification: 400 ×); D: Synaptophysin+ (Magnification: 200 ×).

Figure 4

Immunohistochemical results. A: S100+ expression in schwannoma (Magnification: 200 ×); B: The antigen KI-67 index of the neuroendocrine tumour was approximately 1% (Magnification: 200 ×); C: The KI-67 index of the schwannoma was approximately 1% (Magnification: 200 ×).

Endoscopic resection of the tumour. A: Tumour in the descending part of the duodenum in the natural state; B: Using endoscopic ultrasonography to explore the tumour; C: Endoscopic electrocoagulation for resection of the tumour; D: A titanium clip was used to clamp the wound to stop the bleeding. Pathological manifestation of the tumour under a light microscope. A: Pathological tissue (Magnification: 100 ×). The lower right corner is the nesting tissue of the schwannoma, and the rest is the vesicle-like tissue of the neuroendocrine tumour; B: Neuroendocrine tumour tissue (Magnification: 200 ×); C: Schwannoma tissue (Magnification: 200 ×); D: The vertical incisal margin was negative, and there was no lymphatic vascular invasion (Magnification: 400 ×). Immunohistochemical neuroendocrine tumour results. A: CD56+ (Magnification: 200 ×); B: Chromogranin A+ (Magnification: 200 ×); C: Desmin+ (Magnification: 400 ×); D: Synaptophysin+ (Magnification: 200 ×). Immunohistochemical results. A: S100+ expression in schwannoma (Magnification: 200 ×); B: The antigen KI-67 index of the neuroendocrine tumour was approximately 1% (Magnification: 200 ×); C: The KI-67 index of the schwannoma was approximately 1% (Magnification: 200 ×).

History of past illness

The patient has a history of infection with tuberculosis 40 years ago. The history of surgical trauma was bronchiectasis in 2015, hysterectomy and minimally invasive hysteroptosis in 2020.

Personal and family history

Parents have a history of hypertension.

Physical examination

Mild tenderness in the abdomen, no rebound pain.

Laboratory examinations

Immunohistochemical results showed that the mass was a rare NET with neurilemmoma.

Imaging examinations

Mediastinal computed tomography (CT) showed no tumour metastasis.

MULTIDISCIPLINARY EXPERT CONSULTATION

Because this patient does not have other systemic diseases, multidisciplinary experts were not invited to discuss it.

FINAL DIAGNOSIS

NET of the descending part of the duodenum complicated with schwannoma.

TREATMENT

We removed the tumour by electrocoagulation and gave the patient some other symptomatic treatment to help stopping vomiting and protect the stomach.

OUTCOME AND FOLLOW-UP

Mediastinal CT showed no tumour metastasis, and the prognosis of the patient is good.

DISCUSSION

There may be rare cases of NETs with schwannoma in the descending part of the duodenum worldwide, but there are no clinical reports. To the best of our knowledge, this is the first clinical case report of a duodenal NET complicated with schwannoma, which has high clinical value. Endoscopic NETs and schwannomas of the duodenum do not have specific features and are often mistaken for enlarged duodenal papilla, resulting in missed diagnosis and worsening of the disease. Endoscopic ultrasonography (EUS) is of high value in the diagnosis of these two kinds of tumours. Under EUS, most of the lesions are hypoechoic lesions originating from the submucosa, with clear boundaries and homogeneous internal echoes, which is consistent with our ultrasound results[3]. Duodenal schwannoma is extremely rare in gastrointestinal mesenchymal tumours, and only a few cases have been reported thus far. Duodenal neurilemmoma is often found by accident and is difficult to diagnose before surgery. There was no typical duodenal schwannoma under ordinary endoscopy. Due to the rare nature of duodenal schwannoma, no typical endoscopic ultrasonographic features have been reported[4]. The immunohistochemical results of the specimen remain the gold standard for diagnosis. NET cells are often positive for CgA, CD56, CK, and Syn, while schwannoma cells are often positive for S-100[5], which is consistent with our immunohistochemical results. Endoscopic treatment is usually the first choice for gastrointestinal NETs or schwannomas with diameters less than 1 cm, as it does not invade the lamina propria and because endoscopic treatment has the characteristics of less trauma, less cost, good prognosis, and easy follow-up after the operation[6]. It has been reported that snare polypectomy has a very high complete resection rate of gastrointestinal NETs (93.8%), and this rate may be high for several reasons. First, decoy polypectomy is more commonly used in smaller tumours (< 5.2 mm), and the appearance of polyps is more likely to be limited to the mucosa. The second reason is that electrosurgical devices, such as argon plasma coagulators, damage a larger field of vision during treatment. Therefore, for some small gastrointestinal NETs with specific shapes, the use of decoy electrocoagulation is completely effective[7]. In this case, we used EUS to determine the lesion level and endoscopic electrocoagulation for R0 resection, suggesting the feasibility and broad prospect of early endoscopic diagnosis and treatment of the tumour. The KI-67 index of the specimen was approximately 1%, suggesting that the NET phase was G1. In addition, we examined the vertical edge of the specimen with a high-power microscope. The vertical edge was negative, and there was no lymphatic invasion, which proved that we successfully removed the tumour completely. Mediastinal CT showed no tumour metastasis, and the prognosis of the patient is good.

CONCLUSION

To the best of our knowledge, this is the first publication of a neuroendocrine tumour of descending duodenum complicated with schwannoma. We removed the tumour by electrocoagulation completely and the patient recovered and was discharged.
  7 in total

Review 1.  Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?

Authors:  Andrew M Bellizzi
Journal:  Hum Pathol       Date:  2019-12-17       Impact factor: 3.466

Review 2.  Early Gastroenteropancreatic Neuroendocrine Tumors: Endoscopic Therapy and Surveillance.

Authors:  Hans Scherübl; Guillaume Cadiot
Journal:  Visc Med       Date:  2017-10-10

3.  Gastrointestinal: Schwannoma of the duodenum.

Authors:  Y Mori; A Kurita; S Yazumi
Journal:  J Gastroenterol Hepatol       Date:  2020-05-11       Impact factor: 4.029

4.  Hegemony and cost-effectiveness of endoscopic ultrasound (EUS) in the field of gastroenteropancreatic-neuroendocrine tumors (GEP-NETs).

Authors:  C De Angelis; S F Manfrè; M Bruno; R Pellicano
Journal:  Minerva Med       Date:  2014-10       Impact factor: 4.806

5.  Duodenal schwannoma, an infrequent entity.

Authors:  Lucía Madero Velázquez; Francisco Uceda; Lidia Buendía
Journal:  Rev Esp Enferm Dig       Date:  2021-07       Impact factor: 2.086

6.  Effectiveness of Endoscopic Treatment for Gastrointestinal Neuroendocrine Tumors: A Retrospective Study.

Authors:  Weili Sun; Siyuan Wu; Xiao Han; Chuanhua Yang
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

Review 7.  Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.

Authors:  Bryan Oronsky; Patrick C Ma; Daniel Morgensztern; Corey A Carter
Journal:  Neoplasia       Date:  2017-11-05       Impact factor: 5.715

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.